Morphine alters respiratory control but not other key obstructive sleep apnoea phenotypes: a randomised trial
- PMID: 32165399
- DOI: 10.1183/13993003.01344-2019
Morphine alters respiratory control but not other key obstructive sleep apnoea phenotypes: a randomised trial
Abstract
Accidental opioid-related deaths are increasing. These often occur during sleep. Opioids such as morphine may worsen obstructive sleep apnoea (OSA). Thus, people with OSA may be at greater risk of harm from morphine. Possible mechanisms include respiratory depression and reductions in drive to the pharyngeal muscles to increase upper airway collapsibility. However, the effects of morphine on the four key phenotypic causes of OSA (upper airway collapsibility (pharyngeal critical closure pressure; P crit), pharyngeal muscle responsiveness, respiratory arousal threshold and ventilatory control (loop gain) during sleep) are unknown.21 males with OSA (apnoea-hypopnoea index range 7-67 events·h-1) were studied on two nights (1-week washout) according to a double-blind, randomised, cross-over design (ACTRN12613000858796). Participants received 40 mg of MS-Contin on one visit and placebo on the other. Brief reductions in continuous positive airway pressure (CPAP) from the therapeutic level were delivered to induce airflow limitation during non-rapid eye movement (REM) sleep to quantify the four phenotypic traits. Carbon dioxide was delivered via nasal mask on therapeutic CPAP to quantify hypercapnic ventilatory responses during non-REM sleep.Compared to placebo, 40 mg of morphine did not change P crit (-0.1±2.4 versus -0.4±2.2 cmH2O, p=0.58), genioglossus muscle responsiveness (-2.2 (-0.87 to -5.4) versus -1.2 (-0.3 to -3.5) μV·cmH2O-1, p=0.22) or arousal threshold (-16.7±6.8 versus -15.4±6.0 cmH2O, p=0.41), but did reduce loop gain (-10.1±2.6 versus -4.4±2.1, p=0.04) and hypercapnic ventilatory responses (7.3±1.2 versus 6.1±1.5 L·min-1, p=0.006).Concordant with recent clinical findings, 40 mg of MS-Contin does not systematically impair airway collapsibility, pharyngeal muscle responsiveness or the arousal threshold in moderately severe OSA patients. However, consistent with blunted chemosensitivity, ventilatory control is altered.
Copyright ©ERS 2020.
Conflict of interest statement
Conflict of interest: R.T. Martins reports grants (1043633, 1060992) from National Health and Medical Research Council (NHMRC), during the conduct of the study. Conflict of interest: J.C. Carberry reports grants (1060992) from National Health and Medical Research Council (NHMRC) of Australia and NeuroSleep-Centre for Research Excellence, grants (1043633) from NHMRC, during the conduct of the study. Conflict of interest: D. Wang reports grants (1043633, 1060992) from National Health and Medical Research Council of Australia (NHMRC), during the conduct of the study. Conflict of interest: L. Rowsell reports grants (1043633, 1060992) from National Health and Medical Research Council of Australia (NHMRC), during the conduct of the study. Conflict of interest: R.R. Grunstein reports grants (1043633, 1060992) from National Health and Medical Research Council of Australia (NHMRC), during the conduct of the study; Collaborative Research Centre (CRC) consortium grant between the Australian government, academia and industry (Philips Healthcare as major industry partner), and has participated on advisory board for Teva and Merck, outside the submitted work. Conflict of interest: D.J. Eckert reports grants (1043633, 1060992) from National Health and Medical Research Council of Australia (NHMRC), during the conduct of the study; grants and personal fees for consultancy from Bayer, grants and personal fees for consultancy and advisory board work from Apnimed, and a Collaborative Research Centre (CRC-P) consortium grant between the Australian government, academia and industry, outside the submitted work.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous